Natera Tech in 300+ Studies Highlights Precision Medicine Leadership
Natera, Inc. (NASDAQ: NTRA), a world chief in cell-free DNA testing and precision medication, right this moment introduced the publication of greater than 300 peer-reviewed papers that includes its know-how and reinforcing its long-standing dedication to sturdy medical proof and scientific analysis.
These publications span high-impact journals – corresponding to Nature, Nature Medication, the American Journal of Transplantation and American Journal of Obstetrics and Gynecology – and spotlight breakthroughs corresponding to earlier detection of illness and improved medical decision-making.
This milestone contains:
- Over 150 publications that includes Natera’s oncology portfolio, with greater than 140 targeted on the utility of Signatera
throughout a number of varieties of most cancers. - Greater than 100 publications on its Girls’s Well being applied sciences, showcasing sturdy datasets on non-invasive prenatal testing, provider screening and different purposes.
- Over 60 publications associated to its Organ Well being options, with vital proof throughout coronary heart, kidney and lung transplantation.
“Reaching 300 peer-reviewed publications is a robust testomony to the depth of our scientific funding and the worth our know-how brings to sufferers,” stated Minetta Liu, M.D., chief medical officer for oncology at Natera. “These knowledge display our dedication to bettering medical care throughout disciplines. We’re grateful to our analysis collaborators and the numerous sufferers who make this work doable.”
The put up Natera Tech in 300+ Studies Highlights Precision Medicine Leadership first appeared on AI-Tech Park.
